Quick Dispatch:
Your surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes ships.
Need Help?
Questions about surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes in your area.
SURMOUNT-1 Trial
24.89
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
27.78
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
28.32
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
26.54
For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The
26.16
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
28.23
SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized,
20.94
